Pfizer Inc. (NYSE:PFE) Shares Bought by Goodman Financial Corp

Key Points

• Goodman Financial Corp increased its holding in Pfizer Inc. by 2.9%, acquiring an additional 12,331 shares during the 1st quarter, now totaling 444,602 shares valued at approximately $11.27 million.
• Pfizer's recent earnings report indicated earnings per share (EPS) of $0.92, exceeding analysts' expectations, although revenue decreased by 7.8% year-over-year to $13.72 billion.
• The company announced a quarterly dividend of $0.43, representing an annualized dividend of $1.72 and a dividend yield of 7.22%, with a payout ratio of 124.64%.

Goodman Financial Corp increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 2.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 444,602 shares of the biopharmaceutical company's stock after buying an additional 12,331 shares during the period. Pfizer comprises approximately 2.4% of Goodman Financial Corp's investment portfolio, making the stock its 26th biggest holding. Goodman Financial Corp's holdings in Pfizer were worth $11,266,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bessemer Group Inc. grew its holdings in shares of Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its holdings in shares of Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer during the first quarter valued at $8,283,000. Alta Advisers Ltd grew its holdings in shares of Pfizer by 69.6% during the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after buying an additional 13,100 shares during the last quarter. Finally, WCM Investment Management LLC grew its holdings in shares of Pfizer by 8.7% during the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after buying an additional 10,051 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE traded up $0.20 during mid-day trading on Friday, hitting $23.49. 51,287,529 shares of the company were exchanged, compared to its average volume of 38,018,180. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.32. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a 50 day moving average of $24.36 and a 200-day moving average of $24.60. The stock has a market cap of $133.55 billion, a price-to-earnings ratio of 17.02, a price-to-earnings-growth ratio of 0.84 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The company's revenue for the quarter was down 7.8% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is 124.64%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PFE shares. BMO Capital Markets dropped their price objective on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. The Goldman Sachs Group upped their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Morgan Stanley upped their price target on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. Finally, Bank of America upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $28.28.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.